Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Consensus Rating of “Hold” by Analysts

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been assigned an average rating of “Hold” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $56.40.

A number of equities research analysts recently issued reports on PSTV shares. Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Tuesday, April 21st. D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Finally, Ascendiant Capital Markets lowered their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a report on Monday, June 8th.

Plus Therapeutics Price Performance

Shares of NASDAQ PSTV opened at $5.01 on Friday. The company has a market cap of $34.47 million, a PE ratio of -2.18 and a beta of 1.38. Plus Therapeutics has a 12 month low of $2.90 and a 12 month high of $23.42. The company has a 50-day simple moving average of $5.70 and a 200-day simple moving average of $8.38.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.97 million. On average, analysts anticipate that Plus Therapeutics will post -3.76 EPS for the current year.

Institutional Investors Weigh In On Plus Therapeutics

Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in Plus Therapeutics during the second quarter valued at approximately $41,000. Susquehanna International Group LLP acquired a new position in Plus Therapeutics during the third quarter valued at approximately $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the third quarter valued at approximately $100,000. XTX Topco Ltd acquired a new position in Plus Therapeutics during the fourth quarter valued at approximately $127,000. Finally, State Street Corp lifted its position in Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after buying an additional 127,000 shares in the last quarter. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.